5608 Results

People

  1. Motzer
    Motzer
  2. Scher
    Scher
  3. Solit
    Solit
  4. Morris
    Morris
  5. Bajorin
    Bajorin
  6. Rosenberg
    Rosenberg
  7. Berger
    Berger
  8. Iyer
    Iyer
  9. Reuter
    Reuter
  10. Feldman
    Feldman

Groups

  1. Genitourinary Oncology Service (5608)
  2. Solid Tumor Oncology Division (5608)
  3. Department of Medicine (5598)
  4. GSK Faculty (1640)
  5. Human Oncology and Pathogenesis Program (1139)
  6. Department of Pathology and Laboratory Medicine (1034)
  7. Surgery (1000)
  8. Epidemiology and Biostatistics (864)
  9. Survivorship Research (773)
  10. Urology (769)
  1. "Genitourinary Oncology Service"
Formats
  1. Journal Article (2745)
  2. Meeting Abstract (2507)
  3. Review (113)
  4. Book Section (82)
  5. Editorial (52)
  6. Correspondence (33)
  7. Conference Paper (29)
  8. Guidelines (24)
  9. Research Letter (15)
  10. Book Whole (4)
  11. Miscellaneous (4)
Groups
  1. Genitourinary Oncology Service (5608)
  2. Solid Tumor Oncology Division (5608)
  3. Department of Medicine (5598)
  4. GSK Faculty (1640)
  5. Human Oncology and Pathogenesis Program (1139)
  6. Department of Pathology and Laboratory Medicine (1034)

More Groups

People
  1. Robert Motzer (1243)
  2. Howard Scher (1130)
  3. David Solit (779)
  4. Dean Bajorin (657)
  5. Michael Morris (577)
  6. Jonathan Rosenberg (510)

More People

Years
  1. 2025 (118)
  2. 2024 (293)
  3. 2023 (283)
  4. 2022 (314)
  5. 2021 (341)
  6. 2020 (352)

More Years

Publications
  1. Journal of Clinical Oncology (1697)
  2. Annals of Oncology (303)
  3. Clinical Cancer Research (282)
  4. Cancer Research (245)
  5. Cancer (125)
  6. European Urology (118)

More Publications

Publishers
  1. American Society of Clinical Oncology (1757)
  2. American Association for Cancer Research (688)
  3. Oxford University Press (408)
  4. Elsevier Science, Inc. (389)
  5. Elsevier Inc. (384)
  6. Nature Publishing Group (294)

More Publishers

Results (5608)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Primary retroperitoneal lymph node dissection (RPLND) for non-seminomatous germ-cell tumor (NSGCT): Impact of trends in patient selection on retroperitoneal pathology and outcome
    Meeting Abstract

    Stephenson, A. J.; Bosl, G. J.; Motzer, R. J.; Bajorin, D. F.; Stasi, J. P.; Sheinfeld, J.
    Journal of Clinical Oncology (2004)

    Fulltext@MSK | Save
  • Phase 1 pharmacokinetic and pharmacodynamic trial of docetaxel and 17AAG (17-allylamino-17-demethoxygaidanamycin)
    Meeting Abstract

    Solit, D. B.; Egorin, M.; Valentin, G.; Delacruz, A.; Ye, Q.; Schwartz, L.; Larson, S.; Rosen, N.; Scher, H. I.
    Journal of Clinical Oncology (2004)

    Fulltext@MSK | Save
  • Update of a phase 1 study of intravenous CCI-779 given in combination with interferon-alpha to patients with advanced renal cell carcinoma
    Meeting Abstract

    Smith, J. W.; Ko, Y. J.; Dutcher, J.; Hudes, G.; Escudier, B.; Motzer, R.; Negrier, S.; Duclos, B.; Galand, L.; Strauss, L.
    Journal of Clinical Oncology (2004)

    Fulltext@MSK | Save
  • MSKCC Quality Assessment (QA) monitoring program for potentially harmful chemotherapy orders
    Meeting Abstract

    Sklarin, N. T.; Timoney, J.; Kampel, L.; Hydzik, C.; Savage, J.; Capobianco, M.; Miransky, J.; Haspel, J.
    Journal of Clinical Oncology (2004)

    Fulltext@MSK | Save
  • Changing demographics and the contemporary surgical management of renal cortical tumors
    Meeting Abstract

    Russo, P.; Snyder, M. E.; Rabbani, F.; Kattan, M. W.; Motzer, R.; Reuter, V.
    Journal of Clinical Oncology (2004)

    Fulltext@MSK | Save
  • A phase I dose finding study of weekly, sequential docetaxel (Doc) followed by flavopiridol (F) in patients with advanced solid tumors
    Meeting Abstract

    Rathkopf, D.; Fornier, M.; Shah, M.; Kortmansky, J.; O'reilly, E.; King, A.; Winkelmann, J.; Kelsen, D. P.; Olsen, S.; Schwartz, G. K.
    Journal of Clinical Oncology (2004)

    Fulltext@MSK | Save
  • Phase II trial of cisplatin (C), fixed-dose rate gemcitabine (G) and gefitinib for advanced transitional cell carcinoma (TCC) of the urothelial tract: Preliminary results of CALGB 90102
    Meeting Abstract

    Philips, G.; Halabi, S.; Sanford, B.; Bajorin, D.; Small, E.
    Journal of Clinical Oncology (2004)

    Fulltext@MSK | Save
  • Hormonal induction followed by rapid hormonal cycling for prostate cancer (PC): The MEN's Cycle
    Meeting Abstract

    Nordquist, L.; Sauter, N.; Morris, M.; Smaletz, O.; Konopelski, K.; Delacruz, A.; Heller, G.; Scher, H. I.
    Journal of Clinical Oncology (2004)

    Fulltext@MSK | Save
  • Use of MR spectroscopy and functional imaging in the treatment planning of gliomas
    Meeting Abstract

    Narayana, A.; Chang, J.; Thakur, S.; Huang, W.; Kowalski, A.; Perera, G.; Karimi, S.; Holodny, A.; Hunt, M.; Amols, H.; more...
    International Journal of Radiation Oncology, Biology, Physics (2004)

    Fulltext@MSK | Save
  • SUO11248, a novel tyrosine kinase inhibitor, shows antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma: Results of a phase 2 trial
    Meeting Abstract

    Motzer, R. J.; Rini, B. I.; Michaelson, M. D.; Redman, B. G.; Hudes, G. R.; Wilding, G.; Figlin, R. A.; Zhu, J.; Kim, S. T.; Baum, C.
    Journal of Clinical Oncology (2004)

    Fulltext@MSK | Save